Sunlight vs Embody: Pricing, shipping, and medication options

Sunlight vs Embody is a price and product trade-off: Sunlight advertises personalized GLP-1 plans starting at $88/mo with injections and oral options and a “same price forever” promise, while Embody advertises compounded semaglutide at $69/month (was $299) and compounded tirzepatide at $119/month with free 1–2 day shipping. Early verdict: choose Sunlight if you want branded-presence messaging, injection and oral options, and a stated same-price-forever policy; choose Embody if your main priority is the lowest entry price for compounded semaglutide and fastest delivery after approval.

Explore Sunlight plans from $88/mo

How they differ at a glance

This comparison focuses on the most distinctive differences supplied in the source material: price entry and structure, medication type (compounded versus platform claims), shipping speed and delivery, and program features such as telehealth and pricing commitments. Both platforms include prescription telehealth visits and free shipping in 1–2 days per their landing pages, but the details and qualifiers differ.

1) Price entry and pricing commitments

Sunlight: Advertising “Personalized GLP-1 from $88/mo” and multiple claims including “Same price forever” and “No price increases ever, no hidden fees.” The source repeatedly states starting price and same-price claims and a Summer Promo mention “As low as $88.”

Embody: Advertises a lower entry price for compounded semaglutide at $69/month (was $299) and compounded tirzepatide at $119/month, noting the $69 price is a limited-time offer that may increase and that final pricing may vary based on dose and clinician recommendation. Embody’s materials emphasize a flat locked-in monthly pricing while also noting price variability by dose.

See Embody pricing: $69/mo semaglutide

2) Medication type and regulatory notes

Sunlight: Markets “Personalized GLP-1” with injections and oral options. The source includes a regulatory note: “Medication-specific approval status must be confirmed; branded and compounded products are not interchangeable.”

Embody: Offers compounded semaglutide and compounded tirzepatide. The source explicitly states that compounded medications are not FDA-approved finished products and are not reviewed by FDA for safety, effectiveness or quality. Embody also frames its offering as compounded products filled at a licensed pharmacy after licensed provider review.

3) Shipping and delivery

Sunlight: Source states “Fast, Free Shipping” and “Free shipping in 1-2 days” on the landing-page evidence and multiple shipping calls to action.

Embody: Also advertises free shipping with delivery in 1–2 days after clinician approval and specifically highlights fast 1–2 day delivery as part of the offering.

4) Program features and support

Sunlight: Promotes “100% online medical visit” with injections and oral options and highlights prescription and telehealth included with no insurance required, plus marketing claims about customer support and clinician dose adjustments in testimonials captured on the landing page.

Embody: Emphasizes licensed provider review handled online, prescription and telemed visits included, no insurance required, and positions itself as a lean, no-frills program with 24/7 support access for dosing and side-effect questions. The source notes fewer premium features like integrated coaching compared with higher-priced platforms.

Comparison table: Sunlight vs Embody

What user stories and trade-offs the sources support

Cost-driven users: Embody is presented as the lowest entry price for semaglutide at $69/month on the landing page, and the source frames Embody as “right for cost-driven patients” who accept compounded medication and fewer premium features.

Want broader options and pricing promises: Sunlight markets injections and oral options and repeatedly claims “Same price forever” and a starting price of $88/mo with promotional language about fast, free shipping and no monthly membership.

Start Sunlight’s personalized GLP-1 plan

Final thoughts on Sunlight vs Embody

Sunlight vs Embody is a contrast between platform promises and low-cost compounded offerings. Sunlight emphasizes personalized plans, injection and oral options, and a same-price-forever claim with a starting price of $88/mo. Embody emphasizes the lowest advertised entry point for compounded semaglutide at $69/mo, compounded tirzepatide at $119/mo, and fast free shipping in 1–2 days after approval, while noting compounded medication limitations.

Get Embody’s $69/mo semaglutide offer

Choose one if…

• Choose Sunlight if you prioritize injection and oral options, a personalized GLP-1 program, and the landing-page claim of “Same price forever” and $88/mo starting messaging.
• Choose Embody if your priority is the lowest advertised entry price for compounded semaglutide at $69/mo, compounded tirzepatide at $119/mo, and fast 1–2 day shipping after clinician approval, understanding compounded medications are not FDA-approved finished products.

Both providers require a clinician review and the sources advise confirming eligibility, specific medication approval status, pharmacy details and state availability before enrollment. This comparison uses only the captured landing-page claims and regulatory notes supplied in the source material.